A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers (20130193)

07/10/2016
01/07/2024
EU PAS number:
EUPAS15128
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol-Published Original talimogene laherparepvec 20130193 .pdf

English (5.89 MB - PDF) View document
Updated protocol

Protocol-Published Superseding talimogene laherparepvec 20130193 5 .pdf

First published: 29/02/2024
English (4.86 MB - PDF) View document
Study results
Study report
Other information